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Abstract 
Traditionally, cancer therapies are generally non-specific treatments meant to eradicate 
cancer cells. This can result in death of healthy tissue, which can significantly affect the 
overall well-being of the patient during and after treatment. Immunotherapy offers a more 
targeted approach by using immune cells to specifically identify and kill cancer cells 
through various neoantigens presented on the surface of the cancer cell. Drugs that target 
and block PD-(L)1 and CTLA-4, known as checkpoint inhibitors, act to “cut the breaks” 
on the immune response and keep it actively seeking out and killing cancer cells. Many 
patients fail on these treatments due to a lack of CD8+ T cells, and other cytotoxic 
immune cells, being called into the tumor microenvironment. Many therapies exist to 
work in combination with checkpoint inhibitors to turn these immunologically “cold” 
tumors “hot” and prolong an immune response. I postulated that blocking PD-1, CD47, 
and SEMA4D in a novel triple combination treatment will allow for a greater presence of 
CD8+ T cells into the tumor microenvironment and double the overall response rate of 
patients. In a clinical trial consisting of 200 patients, half were placed into the control 
receiving Pembrolizumab (anti-PD-1) and TTI-621 (anti-CD47), while the experimental 
group received the triple treatment of Pembrolizumab, TTI-621, and Pepinemab (anti-
SEMA4D). Results indicated that the triple combination treatment was effective in 
improving progression-free survival, overall survival, and overall response rate compared 
to that of the control. This clinical trial supports that this triple combination treatment can 
be potentially used as a cancer therapeutic in the future. 
 
 1 
Introduction 
 
Summary of immuno-oncology and cold tumor concept 
For decades, the leading treatment for a majority of cancers has been a triad of surgery, 
chemotherapy, and radiation. These treatment options are generally non-specific towards cancer 
cells and result in a massive deterioration of the patient’s healthy cells and overall quality of life. 
While this blanket approach has been effective in eliminating many individuals’ cancers and 
improving survivorship, there are a number of cancers that remain elusive to treatments or end 
up resurging years later. Throughout the history of cancer research, there have been marked 
advancements that support the fact that not every cancer is the same. Each cancer has a different 
combination of multiple mutations that affect an array of aspects of the cell cycle, angiogenesis, 
and anchorage dependence. Essentially, every tumor has a different mode of attack that can vary 
from patient to patient, or even within the tumor itself. Because of this cancer diversity, cancer 
researchers have been attempting to create more targeted therapies that will be special to a 
patient’s specific type of cancer. 
 
The human body has an incredible arsenal against cancerous growths. Heavy regulation of the 
cell cycle, DNA repair mechanisms, and pro-apoptotic mechanisms all seem to exist in order to 
thwart any rogue cell from establishing itself and harming the host organism. Despite the body’s 
defenses against cancer, the cancerous cells can still manage to evolve and find a way to bypass 
these innate checks and balances. A normal cell can become transformed via the accumulation of 
mutations. Mutations specifically affecting some aspect of the cell cycle and cell growth aide in 
the transformed cell securing an advantage. Cancers will also accrue more mutations over time 
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allowing them to change their tactics along the way or add in their repertoire against the body’s 
defenses. This wide array of potential cancer phenotypes can seem like a perpetual arms race to 
beat the cancer first thus making the development of effective treatments very difficult.  In the 
1980s, a relatively novel approach surfaced: Immuno-oncology (Decker et. al., 2017). Cancer 
Immunotherapy is a class of treatment options that uses the host’s immune system to target, kill, 
and eliminate tumor cells just as it would a foreign bacterial or viral invader. Compared to other 
more traditional and broad-spectrum methods of cancer treatment, immunotherapy offers a more 
targeted approach, which would improve the quality of life for the patient by reducing negative, 
and potentially dangerous, side effects. Chemotherapy is a nonspecific treatment type that attacks 
rapidly dividing cells. While this may effectively kill cancer cells, it can also result in severe off-
target affects – the killing of the patients’ healthy, rapidly dividing cells such as skin cells and 
the lining of the digestive tract. Immunotherapy acts to target neoantigens – proteins unique to 
cancer cells – recruiting various immune cell types to effectively kill and eliminate cancer cells 
all over the body.  Over the past three decades, the modern immuno-oncology movement has 
quickly exploded and the mechanisms behind its efficacy are being researched, treatments are 
being developed, and clinical trials are underway. 
 
The Human Immune System 
The human immune system utilizes an arsenal of molecular and cellular responses that work to 
recognize, target, and kill foreign entities. The immune response is comprised of two major 
branches – innate immune response and the adaptive immune response. Both aspects work in 
tandem and are responsible for the protection of the host from foreign, pathogenic invaders, such 
as bacteria and viruses, but achieve this through different mechanisms. The innate immune 
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system guards against general invaders and requires no prior exposure to learn what constitutes 
as a foreign invader. Elements of the innate immune system, such as macrophages, natural killer 
(NK) cells, and neutrophils are pre-programmed to recognize substances that are not native to the 
host body and eliminate them through phagocytosis. NK cells are essentially pre-programmed to 
target cancerous cells with the ability to recognize various configurations of cell surface proteins 
that identify the cancer cell. This system has a relatively quick response to non-native entities 
and releases molecules, like cytokines and chemokines, to trigger inflammation. This 
inflammation attracts other cell types – particularly ones involved in the adaptive immune 
response.  
The adaptive immune response is more of a targeted system that acts on specific 
pathogens and is involved with immune memory. It is initiated by the phagocytosis of foreign 
pathogens. Key phagocytic cells, namely macrophages and dendritic cells, recognize foreign 
antigens – proteins presented on the surface of cells – phagocytize the invader, and cleave the 
proteins into small oligopeptides (Weinberg, 2014). Once cleaved, these small protein sequences 
(8-11 residues in length) are presented on a specific antigen presenting region on a Major 
Histocompatibility Complex I or II (MHC-I or MHC-II) complex. (Weinberg, 2014) These 
proteins on the surface of antigen presenting cells (APCs) act to bind with receptors on CD4+ T 
Helper cells (TH) or CD8+ Cytotoxic T cells (TC/ CTLs). TH cells activate B cells initiating their 
replication and activating their maturation. Once activated, B cells produce antibodies that can 
then recognize the specific antigens throughout the body. This represents the humoral response 
of the adaptive immune system. Antibodies can recognize the antigen sequences and opsonize 
the invader or infected cell. This opsonization first neutralizes the target and allows for the 
subsequent phagocytosis by macrophages, attraction of complement molecules, or death by 
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cytotoxic T cells. CD8+ Cytotoxic T cells represent another branch of the adaptive immune 
system – the cell-mediated response. Once mature, CTLs have T-cell receptors (TCRs) that 
allow them to target the antigen that was presented to them. Whenever a CTL comes in contact 
with an antigen recognized by its TCR, it can kill the cell triggering pro-apoptotic cascades. If 
the immune system can be manipulated to target cancer cells, researchers can exploit that as a 
potential treatment option. 
Another aspect of the immune system, and one of the areas for promising immunotherapy 
targets, involves blocking the “off” switch for the immune system. The immune system has a 
natural homeostasis, so when “on” signals (such as cytokines and chemokines) are being 
released, they are also stimulating the “off” signals, through negative feedback, in order to avoid 
a severe overreaction of the immune system (Weinberg, 2014). These “off” signals can induce 
the activation of immunosuppressive cells or immunosuppressive proteins. Regulatory T cells 
(TReg) have the same antigen-specific TCRs that are also expressed by CTLs. This allows for the 
TReg’s to compete with the CTLs for the MHC-I proteins on the outside of cells. In addition, 
Teg’s can secrete compounds to suppress the proliferation of TH and CTLs, which enhances the 
immunosuppressive action.   
Regulatory T cells are not the only immunosuppressive mechanism the human immune 
system can employ. Programmed Cell Death Protein -1 (PD-1) and its ligand, PD-L1, interact in 
order to induce what is known as T cell exhaustion, which results in an inhibition of T cell 
activation and proliferation. PD-L1 is generally not detectable in normal tissue, but an IFN 
gamma response can cause normal cells to upregulate its expression (Simon and Labarriere, 
2017). Some tumor cells have evolved to express PD-L1 in order to block T cell 
activation/proliferation and go unnoticed by T cells thus evading destruction. 
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Checkpoint inhibitors, such as anti-PD-(L)1 and anti-CTLA-4, act to block the pathway 
that regulate the “off” switches of the immune system. This allows the attack cells of the immune 
system to continue working at targeting the tumor cells without a negative regulator. Current 
FDA approved checkpoint inhibitors currently on the market include Anti-PD-1 drugs, such as 
Nivolumab (Opdivo ®) and Pembrolizumab (Keytruda ®), Anti-PD-L1 drugs like 
Atezolizumab, and Anti CTLA-4 drugs like Ipilimumab (Yervoy ®). 
 Since there are many players in the immune system, there are many potential targets for 
immunotherapy. However, just as with other molecular or cellular defenses, cancer evolves yet 
another way to circumvent the body’s defenses. Unfortunately, not all patients respond to 
checkpoint inhibitors. The efficacy of the checkpoint inhibitor treatment is dependent on the 
tumor’s microenvironment (TME), particularly the presence of certain immune cells, such as 
CD8+ Tumor-Infiltrating Lymphocytes (TILs) and PD-L1 expression (Gulfo, 2018). Without 
these cells or protein markers present in the tumor environment, the tumor will not be recognized 
by the body’s immune system. This is referred to as an immunologically “cold” tumor and will 
therefore escape destruction. The TME can be classified into four main types: Type I – IV. An 
immunologically “hot” tumor is one that exhibits a Type I phenotype (Gulfo, 2018). This TME is 
TIL+ and PD-L1+ providing an ideal environment for a checkpoint inhibitor. Blocking PD-(L)1 
keeps the immune system revved up and continually targeting and attacking tumor cells. This is 
possible with TILs already present in the TME – they will continually attack the tumor cells, 
effectively shutting off the negative regulation of an immune response. An immunologically 
“cold” tumor does not have a TME that attracts TILs. Patients that do not respond to checkpoint 
inhibitors typically fall into the Type II- Type IV profiles. The key to an effective checkpoint 
inhibitor is maintaining or triggering a “hot” TME (Gulfo, 2018). 
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How to turn a cold tumor hot – different approaches 
The immune system has a natural homeostasis that regulates its response. It takes a combination 
of signals from various cell types to elicit an immune response as well as numerous negative 
regulators to turn off a response. Because of this natural system of checks and balances, it can be 
difficult to manipulate a particular response with only one approach. Combination approaches 
(Checkpoint inhibitors + another immune target) are being researched for efficacy in cancer 
treatments (Gulfo, 2018). Different targets can be used to initiate a type I interferon response, 
while the checkpoint inhibitors prevent the negative regulation of the natural immune system. 
This continual immune response can then be used to target cancer cells throughout the body. 
Major therapy types include other checkpoint inhibitors (immunomodulators), cancer vaccines, 
oncolytic viruses, CD3 Targets bispecific monoclonal antibodies (mAb), adoptive T cell transfer, 
Monoclonal antibodies, or targeted fusion proteins.  
LAG-3 
LAG-3 is a surface receptor expressed on activated T Cells (Burugu et al., 2018). Binding of 
LAG-3 with its ligand will act as an immune suppressant by influencing the activity of Tregs and 
cytotoxic T cells. When bound to Major Histocompatibility Complex II (MHCII) class proteins, 
Treg activity and proliferation is enhanced. When bound with LAG-3 on Cytotoxic T cells, 
proliferation and cytokine production are reduced, thus supporting an immunosuppressive action 
(ct). Cancer cells can increase their production of MHCII production in order to exploit this 
immunosuppressive mechanism. Blocking LAG-3 diminishes the number of Tregs and restores 
the CD8+ effector T cells, counteracting the immunosuppressive activity and maintaining the 
type I tumor microenvironment for effective checkpoint inhibition. When working in 
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combination, the effects are enhanced with anti PD-1 as evidenced in various clinical trials 
(Burugu et al., 2018). 
TIM-3  
TIM-3 is an immune-inhibitory molecule first found on CD4+ T Helper cells and CD8+ T 
Helper cells. Binding of its ligand, galectin-9, leads to effector T cell death resulting in immune 
tolerance – exhausted T cells. Conversely, ligand binding on Regulatory T cells results in an 
enhanced immunosuppressive action. Blocking of this pathway, when combined with anti PD-1 
therapy, has produced effective results (Burugu et al., 2018). 
TIGIT 
TIGIT is a transmembrane protein receptor that regulates the immune checkpoint on T and NK 
cells. When ligands (CD155, CD112, and Nectin 2) bind, effector functions are inhibited in part 
by the production of IL-10. This immunosuppressive cytokine is responsible for the expression 
of the M2 macrophage phenotype, which is representative of more of an anti-inflammatory 
profile (Chen et al., 2016 and He et al., 2017). 
B7-H3 (CD 276)  
This ligand belonging to the B7 family of molecules that are frequently overexpressed in many 
types of cancers (Burugu et al., 2018). This can be a critical and desirable cancer target/marker 
since it is lacking in healthy tissue. Recent studies have shown that this family of molecules is 
involved in immunosuppressive activity correlated to the increase in production of Interleukin – 
10 (IL-10) and TGF-b as evidenced by Sai Han et al in cervical cancers (Sai Han et al., 2018). 
Functioning in tandem with CTLA-4 and PD-1, the B7-H3 class of molecules can also work to 
suppress T cell activation and proliferation further supporting it as an ideal checkpoint target. In 
addition to its immunosuppressive qualities, B7-H3 molecules have also been found to 
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upregulate the cell cycle in tumor cells, support angiogenesis, and allow for metastasis of various 
tumor types (Burugu et al., 2018 and Castellanos et al., 2017).  
GITR 
GITR is a type II transmembrane receptor found extensively on regulatory T cells, and in lower 
amounts on other immune cells such as effector T cells (Knee et al., 2016). Binding to its ligand 
(GITR-L) inhibits regulatory T cell function by inducing depletion of these cell types and 
activates effector T cells (Burugu et al., 2018 and Knee et al., 2016). 
 
CD47 and SIRPa 
CD47 is a cell surface immunoglobulin that negatively regulates anti-tumor immunity through 
suppression of phagocytosis via the SIRPa receptor on macrophages (Burugu et al., 2018). 
CD47 is expressed on nearly all cell lines, including cancer cells, and is used and exploited by 
cancers as a “don’t eat me” signal. When CD47 found on the surface of a red blood cell binds to 
the SIRPa receptor on the macrophage, it triggers intracellular downstream effectors that inhibit 
phagocytosis (Burugu et al., 2018). To the macrophage, that cell has identified itself as 
something not to “eat.” Cancer cells can exploit this mechanism and express CD47 on their cells. 
This tells the innate immune system to pass by, thus evading destruction. Blockade of the 
CD47/SIRPa interaction through the synthesis of monoclonal antibodies induces phagocytosis of 
cancer cells (Murata et al., 2018). 
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IDO 
IDO is an intracellular enzyme that is found in macrophages and dendritic cells that converts 
tryptophan to kynurenine (Burugu et al., 2018). Less cytosolic tryptophan translates to less T cell 
proliferation. More kynurenine induces apoptosis of TH1 cells and promotes differentiation of 
TH1 cells to T regs. Blocking of IDO results in an increase in T cell response and inhibits tumor 
progression (Burugu et al., 2018). BIN1 is a tumor suppressor that controls expression of IDO 
and is deficient in numerous cancers.  
 
KIR Family (Killer immune-globulin-like receptor) 
This family of receptors is expressed on most NK cells and some T cells (Burugu et al., 2018). 
Some are inhibitory when they bind to MHC molecules (HLA-C/HLA-B), while those on NK 
cells, are used to identify against self-recognition (Burugu et al., 2018). This is an effective tool 
for the cancer since cancer cells are considered to be “self” thus making the targeting of these 
rogue cells difficult. Despite this, inhibiting the KIR receptors and HLA ligands that elicit an 
inhibitory response, the NK activation signals can be bypassed (Burugu et al., 2018). 
 
CD94/NKG2A 
On T cells, this receptor functions as an inhibitory checkpoint and blocking it with The IPH2201 
antibody, can improve antibody-dependent cell cytotoxicity (Burugu et al., 2018). Many cancers 
have elevated NKG2A+ NK cells such as an increase in NKG2A in lung and cervical tumors 
compared to the periphery (Burugu et al., 2018). The highest expression is found in cancers with 
low CD8+ TILs and Ki67 (Burugu et al., 2018).  
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TLR-9 
TLR-9 recognizes a known pathogen signatures (PAMPs) by binding to single stranded 
unmethylated CpG-DNA and induces an inflammatory response in an effort to enhance 
cytotoxicity by way of IFNa expression (Gulfo, 2018). It also induces antigen expression that is 
needed to attract CD8+ TILs making it a desirable target to turn an immunologically cold tumor 
hot. (Gulfo, 2018).  
 
DKK 
Promotes an immune-suppressive tumor microenvironment by increasing the MDSC (Myeloid 
derived tumor suppressor cells) resulting in a suppressed T cell response (D’Amico et al., 2016). 
Another immunosuppressive action of DKK includes a decrease in NK activating ligands on 
tumor cells (Malladi et al., 2016). A decrease in these ligands will reduce interaction with tumor-
targeting NK cells. DKK also increases Th2 polarization and decreases IFNa production all to 
achieve an immunosuppressive tumor microenvironment (Chae et al., 2016).  
 
Agnostic mAbs targeting APCs (Antigen presenting Cells) – CD40 
CD40 is expressed broadly on APCs including DCs, B cells, and monocytes. Antibodies 
targeting CD40 promotes DC maturation and cross-presentation of antigens to T cells. It also 
induces apoptosis of tumor cells and TAM conversion to M1-like macrophages (Ishihara et al., 
2018). 
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DC vaccines 
Dendritic cells are antigen-presenting cells that can be utilized in the regulation of the immune 
response. This provides a workable mechanism to derive vaccines that can be used to enhance 
tumor antigen presentation to T cells (Mastelic-Gavillet et al., 2019). They are generated ex vivo 
and pulsed with specific peptides (protein or whole tumor lysate) and can be used in combination 
with anti-PD-(L)1 or anti-CTLA4 (Mastelic-Gavillet et al., 2019). 
 
Macrophage reprogramming 
Tumor Associated Macrophages are highly immunosuppressive. Antibody blockade of the 
receptor for colony stimulating factor 1 (CSF-1) – highly expressed by TAMs – can reprogram 
them toward an M1 phenotype (Räihä and Puolakkainen, 2018). M1-like macrophage is desired 
for its enhanced antigen presentation, promotes stronger anti-tumor T cell responses and 
synergizes with checkpoint blockade (Räihä and Puolakkainen, 2018). 
 
Immunogenic chemotherapy 
Promotes immunogenic cell death (ICD) through presentation of “eat me signals” via the 
translocation of the chaperone proteins, calreticulin, from the endoplasmic reticulum to the 
surface of the tumor cells leading to the activation of DCs and recruitment of TILs (Wu and 
Waxman, 2018).  
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Oncolytic viruses 
The use of oncolytic viruses results in the direct killing of tumor cells. These viruses can be 
designed to specifically target cancer cells and result in the induction of innate and adaptive 
immune response (Kaufman et al., 2015). Upon infection, tumor cells release ROS and Type I 
IFNa; upon lysis, DAMPs and PAMPs. Oncolytic viruses such as in the drug, T-VEC, have been 
gene edited to integrate immunomodulatory genes like cytokines, chemokines, and T-cell 
stimulatory molecules (Kaufman et al., 2015).  
Targeting tumor vasculature 
Tumor vasculature normalization allows the vessels to be more permissive to tissue perfusion 
and delivery of oxygen, drugs, Antibodies, and T cell infiltration following treatment (Lanitis et 
al., 2015). This treatment type also increases leukocyte adhesion molecules (ICAM-1 and 
VCAM-1), which are anti-VEGFR and anti VEGFR mAbs, and increases chemokines and 
cytokines like IL-10, TNF-a, and CXCL10 which leads to increased lymphocyte infiltration 
(Lanitis et al., 2015). 
 
CAR T cells 
Immune cells that are removed from the patient are then engineered and armed with new proteins 
that have the ability to recognize the cancer. Then, this newly design T cell is given back to the 
patient. Targets antigens found on B cells – CD19 – however, mesothelin (expressed on solid 
tumor cells) could be a potential target for solid tumors (Adusumilli, 2017) (Newick et al., 2016).  
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NK Cell activation/mobilization 
The NK activating receptor is CD16 along with other cell surface receptors. Antibodies can be 
developed to activate this receptor thus activating NK cells and allowing them to target cancer 
cells without prior antigen presentation (Sharma et al., 2017).  
 
Combined Treatment Responses 
While checkpoint inhibitor treatments and cold tumor treatment have allowed for 
improved treatment response and survival compared to checkpoint inhibitor treatment alone, 
response rates are still relatively low (~30%) leaving most patients unresponsive to this 
combination treatment (Trillium Therapeutics, 2019). A recent combination trial run by Trillium 
Therapeutics, has their anti-CD47 drug – TTI-621 – exhibiting a > 50% reduction in CAILS in 
41% of patients (Table 1). The Composite Assessment of Index Lesion Severity (CAILS) ranks 
five aspects of lesion morphology including erythema, scaling, plaque elevation, hypo- or 
hyperpigmentation, and lesion size from 0 to 8. A CAILS score is a method of measure for a 
lesion severity and is commonly used to indicate efficacy of treatments (Olsen et al., 2011). 
While these results are a significant advance in cancer immunotherapy, it does not provide 
significant results in a majority of patients.  
Table 1 
 
 
 
 
 
Drug Response Rate (%) 
TTI-621(Trillium)  
+  
anti-PD-1/PD-L1 
41% with a > 50% reduction in 
CAILS 
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According to Evans et. al. in association with Vaccinex, a class of molecules called 
Semaphorins have been shown to alter cytoskeletal effects of immune cells, endothelial cells, 
and tumor cells influencing how they navigate around the TME. Restricted immune cell access 
into the TME may explain why many other cancer immunotherapy treatments fail. 
Semaphorins are soluble, transmembrane proteins that are ubiquitous throughout immune 
cells, but have been linked to overexpression on certain cancers. Expression of a particular 
member of the semaphorin class – SEMA4D – has been shown to be triggered by hypoxia and 
other factors that are characteristic of the TME and inhibits the movement of immune cells 
(Evans et al., 2015).  According to Evans et. Al., SEMA4D acts as a physical barrier that 
surrounds tumors, subsequently preventing CD8+ T cells from entering the tumor. If TILs are 
prevented from accessing the TME, then they cannot cause any damage to the tumor cells. So, 
while there may be an increase in TILs activated by APCs, if they cannot enter the TME then 
their cytotoxic effects are restricted. As evidenced by Vaccinex, SEMA4D is localized to the 
outer rim of the tumor bed. CD8+ T cells are blocked from entering the TME as evidenced by 
their accumulation around the tumor margin and relatively low concentration within the tumor 
bed. Allowing for increased immune infiltration into the TME may result in more effective 
responses. Vaccinex has shown in clinical trials that patients respond to treatment with anti-
SEMA4D4 (Pepinemab). Treatment with anti-SEMA4D/Mab67 (Pepinemab) effectively breaks 
down the barricade allowing a greater infiltration of cytotoxic immune cells.  
In addition to breaking down the physical barrier SEMA4D creates, Pepinemab treatment 
and a checkpoint inhibitor (Avelumab) also influences the CD8+ T cell to Regulatory T cell 
ration (Teff : Treg) (Preston et al., 2013). Anti-SEMA4D treatment promotes an inflammatory 
response by increasing infiltration of CD8+ T cells and downregulates the expression of 
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Regulatory T cells. These findings not only support that SEMA4D acts as a physical barrier, but 
also that it suppresses an inflammatory response via the regulation of Treg cells.  
 
Concluding Statement 
Checkpoint therapy has provided unprecedented results for a relatively small number of patients. 
It works by preventing the homeostatic mechanisms that act to shut-off of the patient’s immune 
system. In a normal and healthy patient, this regulatory mechanism works to prevent an 
overreaction of the immune system. Cancer cells can exploit this and overexpress either the 
ligands or receptors responsible for silencing immune cells. When treating cancer cells, 
preventing the function of immune system regulators allows for the cytotoxic immune cells to 
work longer on tumor cells effectively eradicating them. However, in order for checkpoint 
inhibitors to be effective, the tumor must be considered immunologically hot, that is have a 
strong interferon gamma signal, that calls various cytotoxic cells to the tumor microenvironment. 
A variety of methods have been employed to turn cold tumors hot and have shown to be 
effective working in combination with a checkpoint inhibitor. Combination treatments work in 
harmony to both call immune cells to the microenvironment and keep the immune system revved 
up to continually target and kill the tumor. Despite the strides made and the dramatic results of 
combination treatments, there are still patients who are unresponsive to treatment indicating that 
the cancer has evolved yet another way to survive and successfully propagate. Recent studies 
have assessed the impact of the presence of SEMA4D on the surface of cancer cells – 
specifically at the tumor bed boundary – effectively acting as a physical barrier preventing T 
cells from entering the tumor. This is an intriguing aspect to investigate and may provide an 
explanation as to why combination treatments do not work for a majority of patients. Patients 
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who do not respond to anti-CD47 and anti-PD-1 combination treatment typically fail in the non-
injected lesions, while there is success in the injected lesions. This indicates that there is a 
sufficient immune response to eradicate the tumor. However, I postulate that non-injected tumors 
are not receiving this large immune response because of the SEMA4D blockade.  If there is a 
physical barrier at the edge of the tumor bed preventing access of immune cells into the tumor 
microenvironment, then all other efforts to attract cytotoxic cells or keep the immune system 
revved up are futile. I am postulating that the blocking of SEMA4D, in combination with 
checkpoint inhibitors and anti-CD47, will then allow the tumor microenvironment to sustain a 
prolonged immune response and double the response rate of patients who otherwise were 
unresponsive to other combination immunotherapies. I am postulating that the augmented effect 
will be mediated by an increase in CD8+: Treg ratio in the tumor microenvironment. 
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Research Design and Methods 
Experiment 1 – Effect of Treatment on Melanoma with Checkpoint Inhibitor, 
Pembrolizumab (Keytruda ®), Anti-CD47 TTI-621 (Trillium), and Anti-SEMA4D 
Pepinemab combination treatment 
 
 
 
Figure 1 – Clinical Trial Design 
 
 
 
 
 
Subjects:
Histologically confirmed 
subcutaneous metastatic 
melanoma (stage IIIA,IIIB, 
or IIIC) exhibiting resistance 
of Pembrolizumab 
(Keytruda ®) after four 
failed months of anti-PD-1 
therapy
10 mg/kg of 
Pembrolizumab and the 
TTI-621 anti-CD47 
treatment
10 mg/kg of 
Pembrolizumab,  TTI-621, 
and Pepinemab (anti-
SEMA4D) treatment
N = 200
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Subjects 
A sample of 200 total patients, 18 years of age or older, with histologically confirmed cutaneous 
melanoma with metastasis to regional lymph nodes and who also exhibit resistance to 
Pembrolizumab (Keytruda ®) were recruited. The patients had to have either stage IIIA 
melanoma, stage IIIB, or stage IIIC disease with no in-transit metastases as defined by the 
American Joint Committee on Cancer 2009 classification, 7th edition. Resistance to 
pembrolizumab indicated after four failed cycles (4 months) of previous anti-PD1 therapy. A 
tumor sample from melanoma-positive lymph nodes was required to be sent for central 
pathological evaluation of PD-L1 expression. Membranous expression of PD-L1 in tumor was 
assessed by means of a clinical trial immunohistochemistry assay (22C3 antibody) and was 
scored on a scale of 0 to 5. A score of 2 was considered to indicate PD-L1 positivity.  
 
Trial Design 
One hundred of the recruited patients were randomly placed in one of two cohorts: the control, 
which will receive 10 mg/kg of Pembrolizumab and the TTI-621 anti-CD47 treatment, and the 
experimental, which will receive 10 mg/kg of Pembrolizumab, TTI-621, and Pepinemab the anti-
SEMA4D treatment. The patients received this dose every 4 weeks for a total of 12 doses 
(approximately 1 year) or until disease recurrence or unacceptable toxic effects occurred. The 
rules regarding the withholding of a dose of either the control or experimental treatment and the 
management of immune-related adverse events are detailed in the protocol, available at 
NEJM.org. The primary end point was progression-free survival. Secondary end points included 
overall survival, ratio of CD8+ T cells to FoxP3 T regulatory cells, safety measures, and 
measures of health-related quality of life (Eggermont et al., 2018) (Preston et al., 2013). 
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Assessments and Clinical Endpoints 
Computed tomography (CT), magnetic resonance imaging (MRI) or both were performed every 
12 weeks for the first 2 years. Progression or metastatic lesions had to be histologically 
confirmed whenever possible. The initial date of progression was also recorded. 
Progression-free survival 
The number of months patients survive without further progression of the disease from the time 
of randomization until the date of first local, regional, or distant metastasis. 
Overall Survival 
The number of months patients survive from the time of randomization until the date death from 
any cause.  
Overall Response Rate 
The response rate will be calculated from the number of complete responders plus the number of 
partial responders in both the control and experimental cohorts. 
Ratio of CD8+ T cells to FoxP3 T regulatory cells 
The number of CD8+ T cells and CD4+CD25+FoxP3+ will be quantified and analyzed using 
staining and immunofluorescence analysis of tissue specimens, confocal microscopy, cell 
quantification, tumor-infiltrating lymphocyte isolation, and flow cytometry.  
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Safety  
Adverse effects were assessed at every CT/MRI session with the use of the National Cancer 
Institute Common Terminology Criteria for Adverse Events, version 4.0, and included a 
complete physical examination along with hematological tests. Immune-related adverse effects 
were determined from the Medical Dictionary for Regulatory Activities terms, which is 
periodically updated.  
 
Consent 
All methods and protocols were outlined for the patient’s understanding and approval. After the 
patients review all necessary features of the clinical trial, written consent was obtained. Patients 
were told that they can withdrawal from the clinical trial at any time for any reason. The entire 
procedure was aligned with the guidelines outline by the Institutional Review Board (IRB) at 
Seton Hall University.  
 
Demographic information 
Patient demographic information was collected from each individual’s personal case-report form. 
Details on sex, age, body mass index (BMI), disease stage, type of lymph node involvement, 
number of positive lymph nodes on pathological testing, ulceration, and PD-L1 expression 
status. 
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Statistical Analysis 
Progression-free survival was estimated with the Kaplan-Meier method. Comparisons between 
the two cohorts were made using log-rank tests at two-sided alpha level. Cox proportional-
hazards model was used to estimate the hazard ratio and its respective confidence interval 
(>95%). All analyses were made with SAS software, version 9.4. Power calculations were 
performed using East Software, version 6.4 (Cytel). A P-value of <0.05 is considered to be 
statistically significant. 
 
Results 
Combination treatment with checkpoint inhibitor, Pembrolizumab (Keytruda ®), Anti-CD47 
TTI-621 (Trillium), and Anti-SEMA4D Pepinemab doubles the response rate of patients 
Patients and Trial Regimen 
A total of 200 patients underwent treatment in two cohorts: combination treatment with 
Pembrolizumab (Keytruda ®) and Anti-CD47 TTI-621 (Trillium) or Pembrolizumab (Keytruda 
®), Anti-CD47 TTI-621 (Trillium), and Pepinemab. Upon initial analysis of patient 
demographics, looking at sex, age, body mass index, disease stage, type of lymph node 
involvement, ulceration, and PD-(L)1 expression (Table 2), the characteristics were found to be 
similar in the two groups.  
 
Efficacy 
The 24-month progression-free survival median was not reached in the experimental 
group with Pembrolizumab (Keytruda ®), Anti-CD47 TTI-621 (Trillium), and Pepinemab 
treatment (Table 3, Fig. 3). The progression-free survival median was 9 months in the control 
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group with Pembrolizumab (Keytruda ®) and Anti-CD47 TTI-621 (Trillium). Progression-free 
survival was significantly higher in the experimental group compared to the control treatment 
(Table 3, Fig. 3) indicated by the hazard ratio. The hazard ratio for progression-free survival was 
0.4 indicating that there were significantly fewer deaths in the experimental group than there 
were in the control group. Same was true for overall survival where the hazard ratio was 0.25, 
the overall survival median was 20.4 months for the control and again, not reached for the 
experimental treatment. The overall response rate for the experimental treatment was 63%, more 
than triple that of the control, which was only 20%.   (Table 3). 
 In addition to overall response rate, overall survival, and progression-free survival, we 
looked for a mechanism behind the results. Across all patients, the average ratio of CD8+ T cells: 
CD4+CD25+FoxP3+ regulatory cells was significantly higher in the patients receiving 
Pembrolizumab (Keytruda ®), Anti-CD47 TTI-621 (Trillium), and Pepinemab treatment 
compared to the control (0.98 compared to 0.32). The same held true when comparing the ratios 
of CD8+:CD4+ T cells (0.27 compared to 0.13 in the control) (Table 4). 
 
Safety 
Adverse effects of any grade considered to be in connection with the trial were assessed 
and occurred in 25% of patients in the experimental group and 37% in the control group (Table 
5). The rates of fatigue or asthenia and of diarrhea were similar in the two trial groups. Adverse 
events of grade 3, 4, or 4 that were related to the trial regimen occurred in about the same 
number of patients in the triple combination group as in the control. Other immune-related 
adverse events of any grade occurred in roughly the same number of individuals with the most 
common being hypothyroidism found predominantly in the experimental group (Tables 5 and 6). 
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 Table 2 – Demographic and Clinical Characteristics of Patients at Baseline. 
Characteristic 
Pembrolizumab 
+ TTI-621+ 
Pepinemab 
(N = 100) 
Pembrolizumab 
+ TTI-621 
(N = 100) 
Sex 
Male 
Female 
 
63 
37 
 
60 
40 
Age 
Median 
<50 yr 
50 – <65 yr 
>65 yr 
 
54 
37 
38 
25 
 
54 
37 
38 
25 
Body-mass Index 
<25 
25 - <30 
> 30 
 
31 
45 
24 
 
37 
39 
24 
Disease Stage at Randomization 
Stage IIIA 
Stage IIIB 
Stage IIIC with 1 – 3 positive lymph nodes 
Stage IIIC with > 4 positive lymph nodes 
 
According to AJCC 2009 Criteria 
Stage IIIA 
Stage IIIB 
Stage IIIC with 1 – 3 positive lymph nodes 
Stage IIIC with > 4 positive lymph nodes 
 
16 
46 
19 
19 
 
 
15 
47 
17 
21 
 
16 
46 
18 
20 
 
 
15 
46 
19 
20 
Type of lymph node involvement 
Microscopic 
 
36 
 
32 
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Macroscopic 64 68 
No of Positive lymph nodes on pathological testing 
1 
2 or 3 
> 4 
 
44 
34 
22 
 
47 
33 
20 
Ulceration 
Yes 
No 
Unknown 
 
40 
45 
15 
 
39 
50 
11 
PD-L1 Expression Status 
Positive 
Negative 
Indeterminate 
 
84 
11 
5 
 
85 
11 
4 
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Table 3 – Efficacy Results 
Endpoint 
Pembrolizumab + 
TTI-621+ 
Pepinemab 
10 mg/kg every 4 
weeks 
(N = 100) 
Pembrolizumab 
+ TTI-621 
10 mg/kg every 4 
weeks 
(N = 100) 
Overall Survival (OS)   
Median NR 20.4 months 
Hazard Ratio (95% CI) 0.25 
p-Value (Stratified log rank) <0.0001 
Progression-Free Survival (PFS)   
Median NR 9 months 
Hazard Ratio (95% CI) 0.4 
p-Value (Stratified log rank) <0.0001 
Overall Response Rate (ORR)   
ORR (95% CI) 63% 20% 
Complete Response Rate 25 2 
Partial Response Rate 38 18 
 
 
Table 4 – Comparisons of T Cell Ratios. 
 Pembrolizumab + TTI-
621+ Pepinemab 
10 mg/kg every 4 weeks 
(N = 100) 
Pembrolizumab +  
TTI-621 
20 mg/kg every 4 weeks 
(N = 100) 
 
Ratios Median Median p-Value 
CD8+/CD4+ 0.27 0.13 0.050 
CD8+/CD4+CD25+FoxP3+ 0.98 0.32 0.027 
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Table 5 – Adverse Reactions Occurring in >10% of Patients 
Adverse Reaction 
Pembrolizumab + TTI-
621+ Pepinemab 
200 mg every 4 weeks 
(N = 100) 
Pembrolizumab + TTI-
621 
200 mg every 4 weeks 
(N = 100) 
All Grades Grades 3-5 All Grades Grades 3-5 
General 
Fatigue 25 3 33 4 
Pyrexia 10 0 8 0 
Metabolism and Nutrition 
Decreased Appetite 17 2 21 2 
Respiratory, Thoracic, and Mediastinal 
Dyspnea 17 2 11 1 
Cough 16 0 11 0 
Skin and subcutaneous tissue 
Rash 15 1 8 0 
Gastrointestinal 
Constipation 12 0 21 1 
Diarrhea 12 1 12 1 
Nausea 12 1 32 1 
Endocrine 
Hypothyroidism 12 0 2 0 
Infections 
Pneumonia 12 7 9 6 
Investigations 
Weight Loss 10 1 7 0 
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Table 6 – Laboratory Abnormalities Worsened from Baseline in > 20% of Patients. 
Laboratory Test Pembrolizumab + TTI-621+ 
Pepinemab 
200 mg every 4 weeks 
(N = 100) 
Pembrolizumab + TTI-
621 
200 mg every 4 weeks 
(N = 100) 
All Grades Grades 3-4 All Grades Grades 3-4 
Chemistry 
Hyperglycemia 52 5 51 5 
Increased ALT 33 5 32 3 
Hypoalbuminemia 33 2 29 1 
Increased AST 31 3 32 2 
Hyponatremia 31 9 32 8 
Increased alkaline phosphatase 29 2 29 0 
Hypocalcemia 25 3 19 1 
Hyperkalemia 23 3 20 2 
Increased prothrombin INR 21 2 15 3 
Hematology  
Anemia 43 4 79 19 
Lymphopenia 30 7 41 13 
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Figure 2 – Kaplan – Meier Curve for Progression-Free Survival 
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Discussion  
Combination immunotherapies have shown to be efficacious in treating many cancers, however, 
there is still a relatively low response rate indicating that there must be another element that is 
preventing tumors from being eliminated. In order for cells from both the innate and adaptive 
immune branches to target and kill cancer cells, they must gain access into the tumor 
microenvironment. SEMA4D is a member of a class of receptors found on many immune cells, 
but is also exploited by many cancers, that has the ability to cause cytoskeletal changes on other 
immune cells effectively blocking their function and access to the tumor. So, while combination 
checkpoint inhibitor therapeutics like Pembrolizumab (Keytruda ®) or Ipilimumab (Yervoy ®) 
may be effective in bypassing homeostatic mechanisms of the immune system, if the immune 
cells cannot physically enter the tumor microenvironment, then these treatments will not show 
results since they are not targeting one of the major issues. This study postulated the effect of 
blocking SEMA4D in conjunction with the combination therapies in order to break down the 
physical barrier giving immune cells continued access to the tumor microenvironment. It was 
hypothesized that this triple combination approach would double response rates and be mediated 
by the increase in CD8+ T cell to Regulatory T cell ratios.  
Results indicate that the overall response rates tripled, and progression-free survival and 
overall survival increased significantly as well. The chances of progression-free survival in the 
experimental group was 60% higher than that of the control and overall survival was 75% higher 
compared to the control. The experimental group also had a significantly stronger overall 
response rate compared to that of the control indicating that these data provide evidence to 
support that this triple immunotherapy treatment is more effective in treating melanoma 
compared to other adjuvant therapies. The differences in adverse effects between the two cohorts 
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were statistically insignificant indicating that this new triple treatment approach is not more or 
less toxic than conventional adjuvant therapies. The demographic information also supports that 
any differences in results between the two groups is due to the different treatment methods and 
not attributed to any other factor. 
The cytotoxic T cell to regulatory T cell ratio also increased in the experimental group 
indicating that more T cells are accessing the tumor bed and fewer regulatory T cells are present 
and acting as a negative control for the immune response. Since SEMA4D has been found to 
bind to T cells and influence their cytoskeletal movement, it can determine what cells are able to 
infiltrate the tumor bed. In order to understand the mechanism behind the improved survival 
rates among patients, we looked at the number of effector T cells compared to the number of 
regulatory T cells. The number of effector T cells increased in the cohort receiving 
Pembrolizumab (Keytruda ®), Anti-CD47 TTI-621 (Trillium), and Pepinemab treatment. This 
was expected since blocking the SEMA4D receptor prevents the altered movement of infiltrating 
T cells thus allowing them to move into the tumor microenvironment.  
 To determine how anti-SEMA4D affected T cell movement, we first calculated 
the ratio of CD8+/CD4+ T cells. CD4+ represent all T helper cells, which includes regulatory T 
cells. T helper cells are responsible for the release of cytokines that can both promote and shut 
off an immune response by activating or inactivating certain immune players. The ratio of 
CD8+/CD4+ T cells was larger in the experimental cohort compared to the control as expected. 
This increased ratio indicates that there are more cytotoxic CD8+ T cells compared to CD4+ T 
helper cells. In order to further narrow down the mechanism, we looked specifically at the 
CD8+/regulatory T cells (CD4+CD25+FoxP3+) ratio where we also see a significant difference 
between the two groups with more cytotoxic CD8+ T cells present after therapy with anti-
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SEMA4D. These data suggest that anti-SEMA4D works by allowing for an increased infiltration 
of cytotoxic T cells effectively suppressing the functioning of regulatory T cells that would 
otherwise downregulate the immune response.  
The results of this clinical trial support the importance of the presence of TILs into the 
tumor microenvironment. Anti-SEMA4D, in combination with other immunotherapies, has 
shown to be an effective defense against the tumor’s effort to shut off the host immune system.  
Based off of these results, this clinical trial can be expanded and increase sample size to 1,000 
individuals for study. Further study may also be done in other cancers as well as determining the 
exact molecular cascade mechanism SEMA4D uses to affect T cell migration. This may be 
useful in the development of future therapeutics.  
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